title: Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model.
abstract: Human respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in infants, young children, elderly persons, and severely immunocompromised patients. Effective postinfection treatments are not widely available, and currently there is no approved vaccine. TMC353121 is a potent RSV fusion inhibitor in vitro, and its ability to reduce viral loads in vivo was demonstrated in cotton rats following prophylactic intravenous administration. Here, the pharmacokinetics of TMC353121 in the cotton rat, which is semipermissive for RSV replication, were further explored to build a pharmacokinetic-pharmacodynamic (PK-PD) model and to estimate the plasma drug levels needed for significant antiviral efficacy. TMC353121 reduced the viral titers in bronchoalveolar lavage fluid in a dose-dependent manner after a single subcutaneous administration and intranasal RSV inoculation 24 h after compound administration. The viral titer reduction and plasma TMC353121 concentration at the time of RSV inoculation were well described using a simple E(max) model with a maximal viral titer reduction (E(max)) of 1.5 log(10). The plasma drug level required to achieve 50% of the E(max) (200 ng/ml) was much higher than the 50% inhibitory concentration observed in vitro in HeLaM cells (0.07 ng/ml). In conclusion, this simple PK-PD approach may be useful in predicting efficacious exposure levels for future RSV inhibitors.
authors.affiliation: Tibotec BVBA, Johnson & Johnson, Generaal De Wittelaan L11B3, Mechelen, Belgium.
authors.forename: Marie-Claude
authors.initials: MC
authors.lastname: Rouan
authors.forename: Tom
authors.initials: T
authors.lastname: Gevers
authors.forename: Dirk
authors.initials: D
authors.lastname: Roymans
authors.forename: Loeckie
authors.initials: L
authors.lastname: de Zwart
authors.forename: David
authors.initials: D
authors.lastname: Nauwelaers
authors.forename: Marc
authors.initials: M
authors.lastname: De Meulder
authors.forename: Pieter
authors.initials: P
authors.lastname: van Remoortere
authors.forename: Marc
authors.initials: M
authors.lastname: Vanstockem
authors.forename: Anil
authors.initials: A
authors.lastname: Koul
authors.forename: Kenny
authors.initials: K
authors.lastname: Simmen
authors.forename: Koen
authors.initials: K
authors.lastname: Andries
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D005260:Female; D008297:Male; D011725:Pyridines / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy* / Q000821:virology; D012136:Respiratory Syncytial Viruses / Q000187:drug effects* / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016205:Sigmodontinae
chemical_list: C528854:2-(6-((2-(3-hydroxypropyl)-5-methylphenylamino)methyl)-2-(3-morpholin-4-ylpropylamino)benzoimidazol-1-ylmethyl)-6-methylpyridin-3-ol; D000998:Antiviral Agents; D001562:Benzimidazoles; D011725:Pyridines
references.citation: Virology. 2002 Jan 5;292(1):70-7
references.pmid: 11878909
references.citation: J Mol Biol. 2007 May 4;368(3):652-65
references.pmid: 17362988
references.citation: Nucleosides Nucleotides Nucleic Acids. 2005;24(5-7):497-501
references.pmid: 16247978
references.citation: Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):308-13
references.pmid: 19966279
references.citation: Antimicrob Agents Chemother. 2002 Mar;46(3):841-7
references.pmid: 11850270
references.citation: Clin Infect Dis. 1997 Dec;25(6):1363-8
references.pmid: 9431379
references.citation: J Med Chem. 2008 Feb 28;51(4):875-96
references.pmid: 18254606
references.citation: Am J Hyg. 1957 Nov;66(3):281-90
references.pmid: 13478578
references.citation: JAMA. 1999 Oct 20;282(15):1440-6
references.pmid: 10535434
references.citation: Am J Hyg. 1957 Nov;66(3):291-300
references.pmid: 13478579
references.citation: Toxicol Appl Pharmacol. 1980 Jan;52(1):99-112
references.pmid: 7361317
references.citation: Antiviral Res. 2005 Oct;68(1):18-26
references.pmid: 16112208
references.citation: Am J Pathol. 1978 Dec;93(3):771-91
references.pmid: 362946
references.citation: Drug Metab Dispos. 1995 Oct;23(10):1028-36
references.pmid: 8654189
references.citation: Antiviral Res. 2003 Nov;60(3):209-19
references.pmid: 14638397
references.citation: Antimicrob Agents Chemother. 2004 Jul;48(7):2448-54
references.pmid: 15215093
references.citation: Pediatr Infect Dis J. 2004 Nov;23(11 Suppl):S228-34
references.pmid: 15577578
references.citation: Clin Microbiol Rev. 2000 Jul;13(3):371-84
references.pmid: 10885982
references.citation: Semin Respir Crit Care Med. 2007 Apr;28(2):243-52
references.pmid: 17458777
references.citation: Eur Respir J. 2004 Jul;24(1):150-6
references.pmid: 15293618
references.citation: J Clin Microbiol. 2005 May;43(5):2356-62
references.pmid: 15872266
references.citation: Virus Res. 1985 Oct;3(3):193-206
references.pmid: 3907188
references.citation: Pediatr Infect Dis J. 2002 Jul;21(7):629-32
references.pmid: 12237593
references.citation: Antimicrob Agents Chemother. 1982 Jan;21(1):125-30
references.pmid: 7044296
references.citation: Rev Med Virol. 2007 Jan-Feb;17(1):5-34
references.pmid: 17004293
references.citation: Lancet. 1999 Sep 4;354(9181):847-52
references.pmid: 10485741
references.citation: JAMA. 2003 Jan 8;289(2):179-86
references.pmid: 12517228
references.citation: N Engl J Med. 1986 Jul 10;315(2):77-81
references.pmid: 3724802